BriaCell enrolls 230+ patients in Phase 3 breast cancer trial, interim data expected in 2026

BriaCell Therapeutics has enrolled over 230 patients in its pivotal Phase 3 Bria-ABC study testing Bria-IMT combined with an immune checkpoint inhibitor for metastatic breast cancer. The trial has screened more than 315 patients and continues to gain strong interest from leading cancer centers. The primary endpoint is overall survival, with interim topline data expected in 2026. Positive results could support FDA approval of Bria-IMT, which currently holds Fast Track designation, potentially offering a new treatment option for advanced breast cancer patients.